Midomafetamine
- Generic Name
- Midomafetamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15NO2
- CAS Number
- 42542-10-9
- Unique Ingredient Identifier
- KE1SEN21RM
- Background
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
- Indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
- Associated Conditions
- -
- Associated Therapies
- -
MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD
- Conditions
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- VA Loma Linda Health Care System
- Target Recruit Count
- 5
- Registration Number
- NCT04264026
- Locations
- 🇺🇸
VA Loma Linda Health Care System, Loma Linda, California, United States
Bristol Imperial MDMA in Alcoholism Study
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 20
- Registration Number
- NCT04158778
- Locations
- 🇬🇧
Study Center: University of Bristol, Bristol, United Kingdom
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)
- Conditions
- Interventions
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Lykos Therapeutics
- Target Recruit Count
- 121
- Registration Number
- NCT04077437
- Locations
- 🇺🇸
New School Research, Los Angeles, California, United States
🇺🇸Aguazul Bluewater, Inc., Boulder, Colorado, United States
🇺🇸Wholeness Center, Fort Collins, Colorado, United States
Stanford Regulating Circuits of the Brain Study - MDMA
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 40
- Registration Number
- NCT04060108
- Locations
- 🇺🇸
Stanford Psychiatry and Behavioral Sciences Department, Palo Alto, California, United States
Effects of Drugs on Responses to Brain and Emotional Processes
- Conditions
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 22
- Registration Number
- NCT04053036
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- MAPS Europe B.V.
- Target Recruit Count
- 21
- Registration Number
- NCT04030169
- Locations
- 🇩🇪
Charité - Universitätsmedizin, Berlin Campus Benjamin Franklin, Berlin, Germany
🇬🇧The Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom
🇳🇱Stichting Centrum '45/Arq, Oegstgeest, Noord Holand, Netherlands
Effect of Stimulant Drugs on Social Perception
- Conditions
- Interventions
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 36
- Registration Number
- NCT03790618
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.
- First Posted Date
- 2018-11-26
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Yale University
- Registration Number
- NCT03752918
- Locations
- 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction
- First Posted Date
- 2018-05-17
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 30
- Registration Number
- NCT03527316
- Locations
- 🇨🇭
Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland
Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Lykos Therapeutics
- Target Recruit Count
- 38
- Registration Number
- NCT03282123
- Locations
- 🇺🇸
Zen Therapeutic Solutions, LLC, Mount Pleasant, South Carolina, United States
🇺🇸Affective Care, New York, New York, United States
🇺🇸New School Research LLC, North Hollywood, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.